A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. by Sierra, J et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
A single dose of pegfilgrastim compared with daily filgrastim for 
supporting neutrophil recovery in patients treated for 
low-to-intermediate risk acute myeloid leukemia: results from a 
randomized, double-blind, phase 2 trial
Jorge Sierra*1, Jeffrey Szer2, Jeannine Kassis3, Richard Herrmann4, 
Mario Lazzarino5, Xavier Thomas6, Stephen J Noga7, Nigel Baker8, 
Roger Dansey9 and Alberto Bosi10
Address: 1Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Department of Clinical Hematology, Royal 
Melbourne Hospital, Melbourne, Australia, 3Department of Hematology, Hospital Maisonneuve-Rosemont, Montreal, Canada, 4Department of 
Hematology, Royal Perth Hospital, Perth, Australia, 5Division of Hematology, IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, 
6Hematology Service, Edouard Herriot Hospital, Lyon, France, 7Department of Medical Oncology/Hematology, Alvin and Lois Lapidus Cancer 
Institute, Baltimore, USA, 8Biostatistics, Amgen Ltd, Cambridge, UK, 9Clinical Development, Amgen Inc., Thousand Oaks, CA, USA and 
10Hematology Unit, Department of Critical Care, University of Florence, Florence, Italy
Email: Jorge Sierra* - jsierra@santpau.es; Jeffrey Szer - jeff.szer@mh.org.au; Jeannine Kassis - jkassis@sympatico.ca; 
Richard Herrmann - richard.herrmann@health.wa.gov.au; Mario Lazzarino - mario.lazzarino@unipv.it; Xavier Thomas - xavier.thomas@chu-
lyon.fr; Stephen J Noga - Snoga@lifebridgehealth.org; Nigel Baker - nbaker@amgen.com; Roger Dansey - rdansey@amgen.com; 
Alberto Bosi - a.bosi@dac.unifi.it
* Corresponding author    
Abstract
Background: Patients with acute myeloid leukemia (AML) are often neutropenic as a result of
their disease. Furthermore, these patients typically experience profound neutropenia following
induction and/or consolidation chemotherapy and this may result in serious, potentially life-
threatening, infection. This randomized, double-blind, phase 2 clinical trial compared the efficacy
and tolerability of pegfilgrastim with filgrastim for assisting neutrophil recovery following induction
and consolidation chemotherapy for de novo AML in patients with low-to-intermediate risk
cytogenetics.
Methods: Patients (n = 84) received one or two courses of standard induction chemotherapy
(idarubicin + cytarabine), followed by one course of consolidation therapy (high-dose cytarabine)
if complete remission was achieved. They were randomized to receive either single-dose
pegfilgrastim 6 mg or daily filgrastim 5 μg/kg, beginning 24 hours after induction and consolidation
chemotherapy.
Results: The median time to recovery from severe neutropenia was 22.0 days for both
pegfilgrastim (n = 42) and filgrastim (n = 41) groups during Induction 1 (difference 0.0 days; 95% CI:
-1.9 to 1.9). During Consolidation, recovery occurred after a median of 17.0 days for pegfilgrastim
versus 16.5 days for filgrastim (difference 0.5 days; 95% CI: -1.1 to 2.1). Therapeutic pegfilgrastim
serum concentrations were maintained throughout neutropenia. Pegfilgrastim was well tolerated,
with an adverse event profile similar to that of filgrastim.
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BMC Cancer 2008, 8:195 http://www.biomedcentral.com/1471-2407/8/195Conclusion: These data suggest no clinically meaningful difference between a single dose of
pegfilgrastim and multiple daily doses of filgrastim for shortening the duration of severe neutropenia
following chemotherapy in de novo AML patients with low-to-intermediate risk cytogenetics.
Trial registration: Clinicaltrials.gov NCT00114764
Background
Acute myeloid leukemia (AML) is characterized by rapid
proliferation of immature clonal myeloid cells, which
leads to failure of normal hematopoiesis. Standard treat-
ment for de novo AML consists of one or two cycles of
intensive induction chemotherapy using cytarabine and
anthracyclines with the aim of achieving complete remis-
sion. This is followed by one or more cycles of consolida-
tion chemotherapy to maintain remission. Initial
remission rates of 60% to 70% are typically achieved in
patients aged less than 60 years [1,2].
As a result of their disease, patients with AML are often
neutropenic before beginning chemotherapy [3]. Moreo-
ver, standard induction and consolidation regimens typi-
cally cause profound and protracted neutropenia, with a
high attendant risk of infection and death [4,5]. The dura-
tion of severe neutropenia is clinically significant, as it is
closely correlated with development of infectious compli-
cations and associated morbidities [6].
Prophylactic use of myeloid growth factors reduces the
severity and duration of neutropenia in patients receiving
myelosuppressive chemotherapy [7-9], including patients
treated for AML [4,5,10]. Pegylated filgrastim (pegfilgras-
tim) has the same mechanism of action as the first gener-
ation agent filgrastim, but has markedly reduced renal
clearance, with neutrophil-mediated clearance being the
major route of elimination. As a result, clearance of pegfil-
grastim is decreased, and serum concentrations are sus-
tained throughout the duration of neutropenia [11]. A
single subcutaneous (SC) dose of pegfilgrastim can pro-
vide neutrophil support for chemotherapy regimens with
a range of myelosuppressive potential in patients treated
for solid tumors [12-14] or lymphoma [15-17], and is as
effective as daily SC doses of filgrastim [13,14].
The aim of the current study was to compare the efficacy
of pegfilgrastim with filgrastim for assisting neutrophil
recovery in patients treated with standard induction and
consolidation chemotherapy for AML.
Methods
Patients
Patients at least 18 years old with histologically confirmed
de novo AML, Eastern Cooperative Oncology Group
(ECOG) performance status ≤ 2, and life expectancy ≥ 3
months (with treatment) were eligible for study participa-
tion. Patients with French American British (FAB) subtype
M3 or M7 were excluded. To avoid the inclusion of unde-
tected secondary or postmyelodysplastic syndrome AML,
high-risk (unfavorable) cytogenetic disease type AML (-5/
del(5q), -7/del(7q), inv(3q), t(3;3), abn 11q23, 20q, 21q,
t(6;9), t(9;22), abn 17p, complex karyotypes (≥ 3 abnor-
malities) [18,19]) were also excluded. Patients with previ-
ously treated AML were not eligible for the study.
Study design
In this randomized, double-blind, multicenter, phase 2
study, patients received a course of standard IA 3+7 induc-
tion chemotherapy (idarubicin 12 mg/m2 days 1–3,
cytarabine 100 mg/m2 twice daily days 1–7) (Induction
1), with a second course given, if necessary, after neu-
trophil recovery had occurred (Induction 2). If complete
remission was achieved (≤ 5% myeloblasts),[20] patients
received one course of high-dose cytarabine consolidation
therapy (3 g/m2 if aged <55 years, 2 g/m2 if aged ≥ 55 years
or at increased risk for neurotoxicity; administered twice
daily over 3 hours on days 1, 3, and 5).
During days 6 through 8 of Induction 1, patients were
stratified by age (< or ≥ 55 years) and randomized (using
an interactive voice response system [IVRS] and blinded
treatment box number assignment) in a 1:1 ratio to
receive either pegfilgrastim or filgrastim plus comparator-
matched placebo. Separate computer-generated randomi-
zation lists were prepared for each age strata. The IVRS
allocated the treatments in the order indicated in the list
appropriate for the subject's age. Pegfilgrastim (Neulasta®;
Amgen Inc., Thousand Oaks, CA, USA) was administered
as a single SC 6-mg dose approximately 24 hours after
completing chemotherapy. Filgrastim (Neupogen®;
Amgen Inc., Thousand Oaks, CA, USA) 5 μg/kg SC was
administered daily beginning 24 hours after chemother-
apy and continuing until the post-nadir absolute neu-
trophil count (ANC) was ≥ 1.0 × 109/L for 3 consecutive
days or ≥ 10 × 109/L for 1 day. Patients received the
assigned treatment for all courses of chemotherapy. The
total treatment duration was up to 3 months with a 1-
month follow-up assessment. Patients randomized to
active pegfilgrastim also received daily filgrastim-matched
placebo injections until recovery of ANC in each cycle.
Conversely, patients randomized to active daily filgrastim
received a single pegfilgrastim-matched placebo injection
in each cycle. Matched placebo vials were indistinguisha-
ble from those containing active agent. Both pegfilgrastimPage 2 of 10
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ous solutions. Placebo formulations contained the same
excipients with no active agent.
The primary objective of the study was to compare time to
recovery from severe neutropenia for the pegfilgrastim
and filgrastim treatment groups. Other objectives were to
compare the rate of complete remission following induc-
tion chemotherapy, ANC, adverse events, and the inci-
dence and duration of hospitalization, fever, and
intravenous anti-infective use.
In order to confirm that pegfilgrastim concentrations were
maintained during prolonged neutropenia, a pharmacok-
inetic substudy was planned for the timepoint when 60
patients had completed Induction 1. The substudy was
conducted by Amgen personnel (hematologist/oncolo-
gist, biostatistician, safety specialist, and medical affairs
director) not associated with the study.
The study was conducted in accordance with the Declara-
tion of Helsinki and with International Conference on
Harmonization principles of good clinical practice. The
appropriate independent ethics committees or institu-
tional review boards reviewed and approved the protocol
and informed consent forms. Written informed consent
was obtained from all patients before study-specific pro-
cedures were performed.
Pharmacokinetic analysis
Serum samples for determining pegfilgrastim concentra-
tions were collected concurrently with complete blood
count samples in Induction 1 (daily until ANC recovery
occurred) and were analyzed using a validated enzyme-
linked immunosorbent assay (ELISA). Pharmacokinetic
parameters were estimated using noncompartmental
analysis of serum concentration-time data.
Statistical analysis
Statistical methods were descriptive, with two-sided 95%
confidence intervals (CI) for treatment differences calcu-
lated when appropriate. Time to recovery from severe neu-
tropenia (ANC <0.5 × 109/L) was calculated from the first
day of chemotherapy until the first of two consecutive
post-nadir ANC values ≥ 0.5 × 109/L. Patients who did not
develop severe neutropenia were considered recovered at
day 1, and time to recovery was censored (at last ANC
value) for patients who withdrew without recovery,
started the next cycle before recovery, or did not recover.
Summaries of time to neutrophil recovery were derived
using Kaplan-Meier methods. Duration of febrile neutro-
penia (FN) (ANC <0.5 × 109/L and oral temperature ≥
38.0°C) was calculated only in Induction 1 and defined as
the onset time until the first of 2 consecutive days with
resolution of both neutropenia and fever, or until the last
day of the cycle if both parameters had not recovered.
Duration of fever was counted from the first day with an
oral temperature ≥ 38.0°C until the first of 2 consecutive
days with temperature <38.0°C, or the last day of the cycle
if not resolved.
The planned sample size of 120 patients (based on the
width of the 95% CI around the difference between the
median times to ANC recovery in the two groups) was suf-
ficient to estimate treatment differences with acceptable
accuracy. With 60 subjects per treatment group, the half-
width of the 95% CI for the difference between treatment
groups was estimated to be 2 to 3 days. On the basis of a
previous study, it was calculated that the sample size
would provide up to 70% power to provide a preliminary
conclusion of noninferiority. The full analysis set
included all randomized patients who received at least
one dose of pegfilgrastim or filgrastim.
Results
Patients and study conduct
Between March 2003 and April 2004, 84 patients from 27
investigational sites in Australia, Europe, and North
America participated in the trial.
A planned interim analysis (after 60 patients had com-
pleted Induction 1) revealed an apparent difference in
time to recovery from severe neutropenia between the two
treatment groups. In the interests of patient safety, it was
decided to suspend the study (ongoing patients discontin-
ued study treatment and no new patients enrolled). How-
ever, subsequent review of the data by the study sponsor
revealed a statistical programming error in the analysis of
neutrophil recovery: the time to ANC recovery had been
evaluated using a threshold ≥ 2.0 × 109/L instead of ≥ 0.5
× 109/L (the protocol-defined end point). As patients in
the filgrastim arm received treatment until ANC was ≥ 1.0
× 109/L for 3 consecutive days, it was logical that they sur-
passed 2.0 × 109/L earlier than patients receiving pegfil-
grastim. When this programming error was corrected, in
the interim analysis the difference in time to ANC recov-
ery between treatment groups was 0.5 days (95% CI: -1.8
to 2.8). This precision was within the boundaries set when
the study was planned (2–3 days). After careful statistical
consideration, it was decided that the study would not be
restarted, as the potential bias introduced by halting the
study prematurely was felt to be outweighed by the bias
that would have been associated with restarting a partially
unblinded study (note, no patients were unblinded).
Moreover, the reduced sample size was large enough to
estimate with adequate precision any differences between
treatment groups with respect to the primary endpoint.
Of 84 randomized patients administered Induction 1
chemotherapy, 83 (42 pegfilgrastim, 41 filgrastim)Page 3 of 10
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safety. Baseline demographic and patient characteristics
were similar between treatment groups (Table 1). Forty-
six patients (22 pegfilgrastim, 24 filgrastim) received con-
solidation therapy after achieving complete remission.
Because of the small number of patients who received
Induction 2 chemotherapy (1 pegfilgrastim, 3 filgrastim),
most efficacy data are presented for Induction 1 and Con-
solidation only.
Twenty-one patients (50%) in each treatment group com-
pleted the study. No significant differences between treat-
ment groups were observed with respect to reasons for
early withdrawal. Of 42 patients who were withdrawn pre-
maturely, 15 were discontinued due to the early closure of
the study. All but one of these patients (who never
received randomized study medication) were included in
all analyses, using censored values where appropriate.
Only 6 patients (3 per group) had not recovered from
severe neutropenia in Induction 1 at the time of study clo-
sure; these patients were permitted to receive open-label
filgrastim treatment (2 patients in total received addi-
tional filgrastim therapy). The impact on the study of
these early withdrawals at their relevant timepoints was
evaluated in a sensitivity analysis and no effect was seen.
In addition to those withdrawn because of study closure,
an additional 27 patients were withdrawn from the study
prematurely because of: failure to achieve complete remis-
sion (2 pegfilgrastim, 3 filgrastim), clinically significant
delay (>14 days) in administration of consolidation
chemotherapy following remission assessment (4, 1),
adverse events (2, 2), death (1, 2), or other reasons (4, 6).
At least 90% of patients received full dose chemotherapy
(>75% of protocol-specified dose) in Induction 1 and
Consolidation. The median number of filgrastim doses
administered was 16 during Induction 1 and 13 during
Consolidation.
Time to recovery from severe neutropenia
All patients had severe neutropenia in Induction 1, and
ANC recovered in most patients (Table 2). For both treat-
ment groups, the estimated median time to ANC recovery
was 22.0 days (difference between groups 0.0; 95% CI: -
1.9 to 1.9 days) (Figure 1). Results were also similar when
analyzed by age (<55 or ≥ 55 years) and cytogenetic type
(intermediate or favorable), with median time to ANC
recovery ranging from 22.0 to 24.0 days across subgroups
and treatments (data not shown).
During Consolidation, most patients had severe neutro-
penia, and again, ANC recovered in most cases (Table 2).
Median time to ANC recovery was 17.0 days for pegfilgras-
tim versus 16.5 days for filgrastim (difference 0.5; 95% CI:
Table 1: Demographics and disease characteristics
Pegfilgrastim 6 mg Filgrastim 5 μg/kg/day
No. of Patients 42 41
Age
Median (range), years 51 (18–74) 54 (19–79)
< 55 years, n (%) 22 (52%) 21 (51%)
≥ 55 years, n (%) 20 (48%) 20 (49%)
Male, n (%) 22 (52%) 17 (41%)
Baseline ANC, × 109/L
Mean (SD) 2.2 (5.4) 2.3 (4.0)
Median (range) 0.4 (0.0–33.8) 1.0 (0.0–17.4)
Most common FAB Type, n (%)
M1 9 (21%) 9 (22%)
M2 8 (19%) 11 (27%)
M4 12 (29%) 4 (10%)
M4eo 3 (7%) 3 (7%)
M5 4 (10%) 6 (15%)
Cytogenetics, n (%)
Intermediate 34 (81%) 38 (93%)
Favorable 7 (17%) 3 (7%)
Unfavorablea 1 (2%) 0 (0%)
Bone marrow cellularity, n (%)
Hypoplastic 4 (10%) 5 (12%)
Normoplastic 4 (10%) 8 (20%)
Hyperplastic 33 (79%) 28 (68%)
Unknown 1 (2%) 0 (0%)
ANC, absolute neutrophil count; SD, standard deviation; FAB, French American British.
aCytogenetic classification re-evaluated after randomization; patient ineligible, but included in analyses consistent with intent-to-treat principles.Page 4 of 10
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tim) who were classified as ANC recovery failures after
Consolidation had a late ANC nadir after receiving addi-
tional off-study chemotherapy and were not followed up
for sufficient time to document ANC recovery.
ANC profile and pegfilgrastim pharmacokinetics
As shown in Figure 2, median ANC profiles for each treat-
ment group were almost superimposable up to day 21 of
Induction 1. A second peak was observed after day 21 in
the filgrastim group, who received treatment until ANC
recovery.
Kaplan-Meier estimates of time to recovery from severe neutropenia in Induction 1Figure 1
Kaplan-Meier estimates of time to recovery from severe neutropenia in Induction 1.
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Table 2: ANC recovery in Induction 1 and Consolidation
Pegfilgrastim 6 mg (n = 42) Filgrastim 5 μg/kg/day (n = 41)
Induction 1
Number of patients starting cycle 42 41
Number of patients (%) with SN 42 (100%) 41 (100%)
Number of patients (%) with ANC recoverya 35 (83%) 32 (78%)
Median time to ANC recoveryb 22 days 22 days
Range 16, 55 19, 62
Difference between medians (95% CI) 0.0 (-1.9 to 1.9)
Consolidation
Number of patients starting cycle 22 24
Number of patients (%) with SN 20 (91%) 21 (88%)
Number of patients (%) with ANC recoverya 18 (82%) 23 (96%)
Median time to ANC recoveryb 17 days 16.5 days
Range 1, 57 1, 51
Difference between medians (95% CI) 0.5 (-1.1 to 2.1)
ANC, absolute neutrophil count; SN, severe neutropenia (ANC <0.5 × 109/L); CI, confidence interval.
aIncludes patients whose ANC remained at or above 0.5 × 109/L
bNumber of days from start of chemotherapy until the first of 2 consecutive days with ANC ≥ 0.5 × 109/L; time to recovery was set to 1 day for 
patients whose ANC remained at or above 0.5 × 109/LPage 5 of 10
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serum concentrations reached a maximum (181 ng/mL)
72 hours postdose and remained above the clinically rel-
evant threshold (2 ng/mL, derived from modeling) [21]
throughout the prolonged duration of neutropenia
(approximately 21 days). Pegfilgrastim concentrations
declined on ANC recovery, consistent with a neutrophil-
mediated clearance mechanism. A positive correlation
(Spearman rank correlation = 0.485, P = 0.004) was
observed between time to ANC recovery and time to peg-
filgrastim concentration falling below 2 ng/mL (Figure 3).
Febrile neutropenia and fever
Thirty four patients (81%) in the pegfilgrastim group ver-
sus 36 patients (88%) in the filgrastim group developed
FN, according to the protocol-specified definition, during
Induction 1. The median duration (interquartile range) of
FN during this phase was 15 (11, 20) days for the pegfil-
grastim group, versus 14 (11.5, 18.5) days for the filgras-
tim group. The incidence and median (interquartile
range) number of days with fever were similar in both
treatment groups during Induction 1 (90%, 5 (3, 8) days
for pegfilgrastim vs 93%, 6 (3, 12) days for filgrastim).
During Consolidation, fever was reported in more
patients in the pegfilgrastim group (17/22 (77%)) versus
the filgrastim group (14/24 (58%)), but the median dura-
tion (interquartile range) was 2 (2, 3; 2, 2) days in each
group.
Complete remission
At the end of Induction 1, 33 pegfilgrastim (79%) versus
26 filgrastim recipients (63%) achieved complete remis-
sion. Two additional filgrastim recipients achieved com-
plete remission after Induction 2, resulting in overall
complete remission rates of 79% (33/42) in the pegfil-
grastim group versus 68% (28/41) in the filgrastim group.
No difference in complete remission was observed
between treatment groups, overall (95% CI for difference
in proportions: -9% to 29%), or when analyzed by cytoge-
netic type or age group (Figure 4). When rates for patients
with FAB subtype M4 (the subgroup with the largest dif-
ference between treatment groups) were compared with
those having other FAB subtypes, the complete remission
rate was higher within the M4 subtype for pegfilgrastim
patients, however due to the width of the CIs, no clear dif-
ferences emerged ("M4:" pegfilgrastim 14/15 (93%) vs fil-
grastim 5/7 (71%); "Not M4:" pegfilgrastim 18/27 (67%)
vs filgrastim 23/34 (68%)).
Anti-infective use and hospitalization
Nonprophylactic anti-infectives were administered to all
but two patients (both from the filgrastim group) during
Induction 1; the median duration (interquartile range) of
Median absolute neutrophil count for pegfilgrastim and filgrastim recipients in Induction 1Figure 2
Median absolute neutrophil count for pegfilgrastim and filgrastim recipients in Induction 1.
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versus filgrastim recipients (21 (14, 27) days). During
Consolidation, nonprophylactic anti-infective use was
higher in the pegfilgrastim (82%) versus the filgrastim
(67%) group. However, the median (interquartile range)
duration of use was similar in the two groups (pegfilgras-
tim 21 (20, 33) vs filgrastim 21.5 (18, 35.5) days). The
incidence and duration of hospitalization was similar in
the two treatment groups, with nearly all patients being
hospitalized, as per routine clinical practice.
Adverse events
All 83 patients had one or more adverse event. The pattern
of events was consistent with that expected in a popula-
tion receiving intensive chemotherapy for AML and was
similar for the two treatment groups. Treatment-related
adverse events occurred in 11 (26%) pegfilgrastim versus
9 (22%) filgrastim recipients. One of these events (vascu-
lar purpura; pegfilgrastim group) was classified as serious.
The most frequently reported treatment-related adverse
event was bone pain (pegfilgrastim 3 (7%) vs filgrastim 4
(10%)). Two patients (5%) withdrew from each treatment
group as a result of adverse events. Three patients died
during the study (1 pegfilgrastim, 2 filgrastim), all of res-
piratory complications associated with chemotherapy tox-
icity and baseline co-morbid conditions. None of the
deaths were considered related to study drug.
Discussion
This randomized, double-blind phase 2 study was the first
to evaluate use of pegfilgrastim for neutrophil support in
patients receiving chemotherapy for AML. Few studies on
the use of pegfilgrastim in this setting have been pub-
lished and none address the efficacy of pegfilgrastim in
relation to filgrastim.
Treatment was anticipated to induce profound and pro-
tracted neutropenia with a high risk of FN. The efficacy
and safety of filgrastim in this setting was previously dem-
onstrated in a large (n = 521), randomized, double-blind
trial, which showed significant reductions compared with
placebo in the duration of severe neutropenia (P < 0.001)
and fever, anti-infective use, and hospitalization [4]. In
the present study, we found no evidence to suggest a clin-
ically meaningful difference between the efficacies of a
single dose of pegfilgrastim 6 mg or daily filgrastim 5 μg/
kg for reducing time to recovery from severe neutropenia
– the primary endpoint. More than 80% of both treatment
groups developed FN during Induction 1. FN was some-
what prolonged in this phase (median 15 days for pegfil-
grastim vs 14 days for filgrastim), but this probably
reflects the predefined stipulation for resolution of both
fever and neutropenia before the event was considered
resolved. Indeed, the duration of fever was much shorter
than this (median 5 days pegfilgrastim vs 6 days filgras-
Proportion of patients in complete remission overall and by subgroupFigure 4
Proportion of patients in complete remission overall and by subgroup.
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this setting (7 days filgrastim vs 8.5 days placebo) [4].
Serum pegfilgrastim concentrations were sustained
throughout the prolonged period of severe neutropenia
and declined rapidly on ANC recovery. A positive correla-
tion was observed between time to ANC recovery and
time to pegfilgrastim concentration falling below the ther-
apeutic threshold, further supporting the neutrophil-
mediated clearance mechanism for pegfilgrastim. Pegfil-
grastim was well tolerated and the adverse event profile
was comparable to previously published data on filgras-
tim use in AML [4].
Initial complete remission rates in our study were similar
between treatment groups and comparable to results from
previous studies in this setting [4,22-25]. Correlation
between remission induction and improved survival was
clearly demonstrated by Heil et al [4]: median survival
times for patients achieving versus not achieving complete
remission were 18.2 versus 4.4 months. Concerns that
hematopoietic growth factors might stimulate growth of
the myeloid leukemic clone in patients have not been
confirmed in clinical studies: to date, leukemic clone
stimulation has been demonstrated only in vitro [26-28].
Long-term follow up (median 7 years) of patients in the
Heil et al. study showed that filgrastim treatment did not
have any adverse effects on complete remission or long-
term survival rates [29]. Since filgrastim and pegfilgrastim
have the same active moiety, we would expect long-term
outcomes for pegfilgrastim to be consistent with those for
filgrastim.
Patients with unfavorable cytogenetics or secondary,
relapsed, or previously treated AML were excluded from
our study. It is known that neutrophil recovery may be
delayed in such patients, and their exclusion was intended
to minimize heterogeneity with respect to duration of
severe neutropenia and thereby allow precise evaluation
of the impact of the growth factors on neutrophil recovery
time in the two treatment groups. The power of this study
was weakened by early termination of recruitment and by
patient withdrawals. The impact of study closure on the
primary endpoint was balanced between treatment
groups, as the same number of patients were withdrawn
from both groups prior to recovery from severe neutrope-
Relationship between days to pegfilgrastim concentration falling below 2 ng/mL and days to absolute neutrophil count > 0.5 × 109/LFigure 3
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definition of non-inferiority was planned, instead the
study was designed to have sufficient subjects to estimate
the difference between the groups in time to neutrophil
recovery within ± 2–3 days, which was predefined as the
period pertaining to a clinically relevant difference.
Despite early termination of the study, which resulted in
reduced patient numbers, the 95% CI observed (± 1.9
days) was narrower than that constituting a clinically rel-
evant difference in neutrophil recovery between pegfil-
grastim- and filgrastim-treated patients. Within this
context, our findings provide no evidence of a clinically
relevant difference between the treatment strategies. Data
regarding secondary endpoints must, however, be inter-
preted within the limits of the revised sample size. Over-
all, given the paucity of data in this setting, the current
study provides valuable information and an evidence base
for the use pegfilgrastim in AML.
Conclusion
In conclusion, data from this phase 2 study suggest no dif-
ference in the efficacy of a single dose of pegfilgrastim
compared with daily doses of filgrastim for reducing the
duration of severe neutropenia in patients receiving
induction and consolidation chemotherapy for low-to-
intermediate risk AML.
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